Compile Data Set for Download or QSAR
Report error Found 190 Enz. Inhib. hit(s) with all data for entry = 13056
TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755426(US20250214932, Example 58)
Affinity DataIC50: 59.7nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755447(US20250214932, Example 79)
Affinity DataIC50: 78.2nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755527(US20250214932, Example 160)
Affinity DataIC50: 78.2nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755391(US20250214932, Example 21)
Affinity DataIC50: 78.2nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755380(US20250214932, Example 9)
Affinity DataIC50: 78.5nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755399(US20250214932, Example 29)
Affinity DataIC50: 102nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755451(US20250214932, Example 84)
Affinity DataIC50: 110nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755383(US20250214932, Example 12)
Affinity DataIC50: 112nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755378(US20250214932, Example 7)
Affinity DataIC50: 118nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755524(US20250214932, Example 157)
Affinity DataIC50: 129nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755428(US20250214932, Example 60)
Affinity DataIC50: 130nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755402(US20250214932, Example 32)
Affinity DataIC50: 139nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755381(US20250214932, Example 10)
Affinity DataIC50: 142nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755427(US20250214932, Example 59)
Affinity DataIC50: 146nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755491(US20250214932, Example 124)
Affinity DataIC50: 149nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755526(US20250214932, Example 159)
Affinity DataIC50: 159nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755525(US20250214932, Example 158)
Affinity DataIC50: 162nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755452(US20250214932, Example 85)
Affinity DataIC50: 163nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755386(US20250214932, Example 16)
Affinity DataIC50: 170nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755436(US20250214932, Example 68)
Affinity DataIC50: 170nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755395(US20250214932, Example 25)
Affinity DataIC50: 174nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755414(US20250214932, Example 44)
Affinity DataIC50: 176nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755372(US20250214932, Example 1)
Affinity DataIC50: 176nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755397(US20250214932, Example 27)
Affinity DataIC50: 182nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755387(US20250214932, Example 17)
Affinity DataIC50: 182nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755520(US20250214932, Example 153)
Affinity DataIC50: 188nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755415(US20250214932, Example 45)
Affinity DataIC50: 191nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755400(US20250214932, Example 30)
Affinity DataIC50: 192nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755417(US20250214932, Example 48)
Affinity DataIC50: 196nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755404(US20250214932, Example 34)
Affinity DataIC50: 199nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755472(US20250214932, Example 105)
Affinity DataIC50: 204nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755416(US20250214932, Example 46)
Affinity DataIC50: 218nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755482(US20250214932, Example 115)
Affinity DataIC50: 219nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755484(US20250214932, Example 117)
Affinity DataIC50: 221nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755476(US20250214932, Example 109)
Affinity DataIC50: 231nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755437(US20250214932, Example 69)
Affinity DataIC50: 235nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755450(US20250214932, Example 82)
Affinity DataIC50: 238nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755384(US20250214932, Example 13)
Affinity DataIC50: 239nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755528(US20250214932, Example 161)
Affinity DataIC50: 252nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755375(US20250214932, Example 4)
Affinity DataIC50: 254nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755421(US20250214932, Example 52)
Affinity DataIC50: 261nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755507(US20250214932, Example 140)
Affinity DataIC50: 283nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755419(US20250214932, Example 50)
Affinity DataIC50: 284nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755409(US20250214932, Example 39)
Affinity DataIC50: 294nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755373(US20250214932, Example 2)
Affinity DataIC50: 294nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755497(US20250214932, Example 130)
Affinity DataIC50: 296nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755423(US20250214932, Example 55)
Affinity DataIC50: 296nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755490(US20250214932, Example 123)
Affinity DataIC50: 297nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755413(US20250214932, Example 43)
Affinity DataIC50: 300nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1G(Human)
Praxis Precision Medicines

US Patent
LigandPNGBDBM755523(US20250214932, Example 156)
Affinity DataIC50: 300nMAssay Description:The compound plate was created at 2× concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

Displayed 1 to 50 (of 190 total ) | Next | Last >>
Jump to: